Clinigen Group Plc (CLIN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Clinigen Group Plc (CLIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013154
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:83
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Clinigen Group plc (Clinigen Group) is a pharmaceutical and services company that provides access to medicines, clinical trials, unlicensed and commercial supply. The company acquires and licenses essential commercial medicines including cardioxane, ethyol, foscavir, savene and vibativ. It offers clinical trial services, IDIS managed access, global access and strategic services. Clinigen Group’s clinical trial services comprise direct-to-site delivery, demand-driven labelling and distribution, ancillary supply, investigator-initiated trial services, and technical consultancy services. It serves pharmaceutical and biotechnology companies; and healthcare professionals. The company has operations in New Zealand, Australia, Japan, the US, Singapore, South Africa and the UK . Clinigen Group is headquartered in Burton-on-Trent, the UK.

Clinigen Group Plc (CLIN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Clinigen Group Plc, Medical Devices Deals, 2011 to YTD 2017 11
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Clinigen Acquires Rights to Totect from Biocodex USA 14
Clinigen Group Acquires Ethyol from AstraZeneca 15
Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 16
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For US$33 Million 17
Partnerships 18
Clinigen Enters into Agreement with Shionogi 18
Clinigen Enters into Distribution Agreement with Romark Labs 19
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 20
Clinigen Group Enters into Distribution Agreement with BioQ Pharma 21
Clinigen Group Partners with Horizon Pharma 22
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 23
Cumberland Pharma Enters into Agreement with Clinigen 24
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 25
Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 26
EirGen Pharma Enters into Agreement with Equity Pharma 27
Licensing Agreements 28
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 28
Clinigen Extends Licensing Agreement with Hospira for Foscavir 29
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 30
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 32
NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 33
Clinigen Enters Into Licensing Agreement With Hospira For Foscavir 34
Link Healthcare Enters into Licensing Agreement with Salix Pharma for Relistor 35
Equity Offering 36
Clinigen Completes IPO For US$16 Million 36
Acquisition 38
Clinigen to Acquire Quantum Pharma for USD199 Million 38
Clinigen Group Acquires Link Healthcare for USD155.2 Million 39
Clinigen Group Acquires Idis Group for USD338 Million 41
Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 43
Clinigen Group Plc – Key Competitors 44
Clinigen Group Plc – Key Employees 45
Clinigen Group Plc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 48
Financial Announcements 48
Sep 28, 2017: Clinigen Group: Full Year Results for the Year Ended 30 June 2017 48
Mar 15, 2017: Clinigen Group: Strong H1 Performance with Adjusted EPS up 31% 49
Jan 25, 2017: Clinigen Group HY trading update: strong H1 performance with gross profit up 34% 56
Sep 28, 2016: Clinigen Group: Transformational Year Delivers 25% Growth In Adjusted EPS 58
Jul 20, 2016: Strong second half performance completes transformational year for Clinigen 67
Mar 02, 2016: Clinigen Group Announces Continued Strong Growth With Eps Up 21% 69
Mar 02, 2016: Continued Strong Growth With EPS Up 21% 75
Jan 19, 2016: Clinigen Group announces Half year trading update-2016 76
Corporate Communications 77
Nov 01, 2017: Clinigen Group: Board changes 77
Sep 28, 2016: Shaun Chilton to take over as Chief Executive Officer 79
Other Significant Developments 80
Jul 18, 2017: Clinigen Group: Year End Trading Update 80
Mar 30, 2016: Clinigen Group has become a full member of the European Alliance for Access to Safe Medicines and Alliance for Safe Online Pharmacy in the EU 82
Appendix 83
Methodology 83
About GlobalData 83
Contact Us 83
Disclaimer 83

List of Tables
Clinigen Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Clinigen Group Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Clinigen Group Plc, Medical Devices Deals, 2011 to YTD 2017 11
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Clinigen Acquires Rights to Totect from Biocodex USA 14
Clinigen Group Acquires Ethyol from AstraZeneca 15
Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 16
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For US$33 Million 17
Clinigen Enters into Agreement with Shionogi 18
Clinigen Enters into Distribution Agreement with Romark Labs 19
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 20
Clinigen Group Enters into Distribution Agreement with BioQ Pharma 21
Clinigen Group Partners with Horizon Pharma 22
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 23
Cumberland Pharma Enters into Agreement with Clinigen 24
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 25
Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 26
EirGen Pharma Enters into Agreement with Equity Pharma 27
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 28
Clinigen Extends Licensing Agreement with Hospira for Foscavir 29
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 30
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 32
NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 33
Clinigen Enters Into Licensing Agreement With Hospira For Foscavir 34
Link Healthcare Enters into Licensing Agreement with Salix Pharma for Relistor 35
Clinigen Completes IPO For US$16 Million 36
Clinigen to Acquire Quantum Pharma for USD199 Million 38
Clinigen Group Acquires Link Healthcare for USD155.2 Million 39
Clinigen Group Acquires Idis Group for USD338 Million 41
Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 43
Clinigen Group Plc, Key Competitors 44
Clinigen Group Plc, Key Employees 45
Clinigen Group Plc, Subsidiaries 46

★海外企業調査レポート[Clinigen Group Plc (CLIN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Net One Systems Co Ltd (7518):企業の財務・戦略的SWOT分析
    Net One Systems Co Ltd (7518) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • NKT AS (NKT):企業の財務・戦略的SWOT分析
    NKT AS (NKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • HSH Nordbank AG:企業のM&A・事業提携・投資動向
    HSH Nordbank AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HSH Nordbank AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Allegiance Capital Corporation:企業の戦略・SWOT・財務分析
    Allegiance Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary Allegiance Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Tokmanni Group Oyj (TOKMAN):企業の財務・戦略的SWOT分析
    Tokmanni Group Oyj (TOKMAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Rajesh Exports Limited
    Rajesh Exports Limited - Strategy, SWOT and Corporate Finance Report Summary Rajesh Exports Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Newfield Exploration Company (NFX)-石油・ガス分野:企業M&A・提携分析
    Summary Newfield Exploration Company (Newfield) is an independent upstream company. The company focuses on onshore large scale, liquids-rich resource plays. Its domestic assets are in the Anadarko and Arkoma basins of Oklahoma, the Williston Basin of North Dakota and the Uinta Basin of Utah. The com …
  • Choppies Enterprises Ltd:企業の戦略的SWOT分析
    Choppies Enterprises Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • AA PLC:企業の戦略・SWOT・財務分析
    AA PLC - Strategy, SWOT and Corporate Finance Report Summary AA PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • BlackBerry Ltd:戦略・SWOT・企業財務分析
    BlackBerry Ltd - Strategy, SWOT and Corporate Finance Report Summary BlackBerry Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Tonix Pharmaceuticals Holding Corp (TNXP):企業の財務・戦略的SWOT分析
    Summary Tonix Pharmaceuticals Holding Corp (Tonix) is a developer of pharmaceutical products to address public health challenges. The company offers pharmaceutical products and treatments for disorders of the central nervous system including fibromyalgia, post traumatic stress disorder and episodic …
  • NOJA Power Switchgear Pty Ltd:企業の戦略的SWOT分析
    NOJA Power Switchgear Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Ebara Corporation:企業の戦略・SWOT・財務分析
    Ebara Corporation - Strategy, SWOT and Corporate Finance Report Summary Ebara Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sun Resources NL (SUR):企業の財務・戦略的SWOT分析
    Summary Sun Resources NL (Sun Resources) is an oil and gas exploration and development company. The company explores and develops crude oil and natural gas. Its services include exploration, production, and development of unconventional oil and gas resources. Its projects include Delta Oil Project, …
  • Xylem Inc.:企業の戦略・SWOT・財務情報
    Xylem Inc. - Strategy, SWOT and Corporate Finance Report Summary Xylem Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Getinge AB:戦略・SWOT・企業財務分析
    Getinge AB - Strategy, SWOT and Corporate Finance Report Summary Getinge AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Cummins Inc (CMI):電力:M&Aディール及び事業提携情報
    Summary Cummins Inc. (Cummins), formerly Cummins Engine Company, is a manufacturer of diesel engines and related technologies. It designs, manufactures, services and distributes engines and related component solutions. The company offers filtration, fuel systems, control systems, after treatment dev …
  • Siluria Technologies Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Siluria Technologies Inc (Siluria) engaged in producing fuels and chemicals from natural gas and low value byproducts. Its products include modus - olefins to gasoline, and gemini - natural gas to ethylene. The company also involved in catalytic process to convert natural gas into liquid fue …
  • BPH Energy Ltd (BPH):企業の財務・戦略的SWOT分析
    BPH Energy Ltd (BPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Globavir Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Globavir Biosciences Inc (Globavir) is a specialty biotechnology company that develop combination of drug therapies and diagnostic tests in the therapeutic areas of infection and immune-oncology. Through Globavir’s Drug Discovery Platform (GDDP), it generates a wide range of small molecule c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆